Study of Cannabidiol CBD to Reduce Opioid Use After Primary Total Knee Replacement Surgery A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

What this Trial Is About

Researchers are evaluating how daily treatment with cannabidiol CBD might affect the need for opioid pain medication, pain, inflammation, and related symptoms after knee replacement surgery. The study aims to better understand if CBD can reduce the use of opioids through its anti-inflammatory, pain-relieving, and anxiety-reducing effects. This is a phase 2, randomized, double-blind, placebo-controlled clinical trial focusing on patients undergoing primary total knee arthroplasty. Participants are divided into four groups. One group takes 300 mg of CBD daily 150 mg twice a day for 36 days starting on the first day, another takes placebo for 7 days before surgery followed by CBD for 29 days after surgery, a third group takes CBD for 7 days before surgery then placebo for 29 days after, and the last group takes placebo throughout the 36 days. CBD is taken orally one hour before or two hours after meals. Dose adjustments are allowed for those who cannot tolerate the full dose. During the study, participants will be monitored for opioid use during the 28 days after surgery, pain intensity, anxiety, sleep disturbances, and inflammation markers. Researchers will collect data on adverse events, liver enzyme levels, and serious side effects over the five weeks of treatment. Follow-up includes patient-reported outcomes and longitudinal assessments to evaluate the impact of CBD on postoperative recovery and opioid consumption.

Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty